; Whereas in fiscal year 2020, pancreatic cancer received its own dedicated research program at the Department of Defense under the Congressionally Directed Medical Research Programs; Whereas in the Department of Defense Appropriations Act, 2020 (division A of Public Law 116–93 ), Congress appropriated funds to the Congressionally Directed Medical Research Programs, with $6,000,000 going to the Pancreatic Cancer Research Program; Whereas during the consideration of H.R. 6395 (the National Defense Authorization Act for Fiscal Year 2021), the House of Representatives agreed to an amendment to the bill that was filed with the Committee on Rules by Representative Carson of Indiana to increase the authorization of funds by $5,000,000 for pancreatic cancer research, including an early detection initiative, by the Department of Defense, and the House of Representatives passed the bill with that amendment included; Whereas during the consideration of H.R. 7617 (the Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Homeland Security, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021), the House of Representatives agreed to an amendment to the bill that was filed with the Committee on Rules by Representative Carson of Indiana and Representative Eshoo to increase the amount appropriated for a pancreatic cancer early detection initiative from $10,000,000 to $15,000,000, and the House of Representatives passed the bill with that amendment included; and Whereas the 116th Congress has a unique opportunity to make a historic investment in pancreatic cancer research at the Department of Defense: Now, therefore, be it